IL-1 receptor antagonist defect (DIRA) in a pediatric patient, receiving adalimumab with good clinical response

Int J Dermatol. 2021 May;60(5):639-640. doi: 10.1111/ijd.15411. Epub 2021 Jan 11.

Authors

Juan Carlos Bustamante-Ogando¹, Selma Scheffler-Mendoza², Marco Antonio Yamazaki-Nakashimada², Marimar Saez-de-Ocariz³

Affiliations

¹ Primary Immunodeficiencies Research Unit, Instituto Nacional de Pediatría, Mexico, Mexico.
² Immunology Department, Instituto Nacional de Pediatría, Mexico, Mexico.
³ Dermatology Department, Instituto Nacional de Pediatría, Mexico, Mexico.

PMID: 33426674
DOI: 10.1111/ijd.15411

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / adverse effects
Antirheumatic Agents* / adverse effects
Child
Homozygote
Humans
Interleukin 1 Receptor Antagonist Protein
Receptors, Interleukin-1*
Tumor Necrosis Factor-alpha

Substances

Antirheumatic Agents
Interleukin 1 Receptor Antagonist Protein
Receptors, Interleukin-1
Tumor Necrosis Factor-alpha
Adalimumab